Clinical trial · Observational
Role of Hysterectomy in the Treatment of Borderline Ovarian Tumors
Role Of Hysterectomy In The Treatment Of Borderline Ovarian Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Borderline ovarian tumors (BOT), are rare epithelial ovarian tumors characterized by the presence of frankly malignant cytologic features in the absence of stromal invasion. Surgical treatment of perimenopausal and postmenopausal BOT requires bilateral adnexectomy. Although some studies have reported an increased recurrence rate in the group of patients treated with uterine preservation, these data are severely limited by the small sample of patients and the presence of confounding factors in the analysis of oncologic outcomes. Determining the impact of hysterectomy on the survival outcomes of perimenopausal and postmenopausal patients diagnosed with early FIGO stage BOT is necessary to avoid overtreatment, hysterectomy being associated with a low but not negligible rate of morbidity and mortality.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hysterectomy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Impact of uterine preservation on the rate of BOT recurrence
- timeFrame
- After surgery during follow up (up to 20 years)
- description
- Impact of uterine preservation on the rate of borderline ovarian tumors (BOT) recurrence and thus its usefulness or otherwise in clinical care practice; therefore, the overall recurrence rate (which includes BOT, invasive BOT implants, and carcinoma) in patients treated with (group 1) and without (group 2) hysterectomy will be determined
Secondary outcomes (6)
- measure
- The rate of recurrence of BOT and of invasive implants
- timeFrame
- After surgery during follow up (up to 20 years)
- description
- Improved care practice by determining in patients with BOT undergoing (group 1) or not undergoing (group 2) hysterectomy the rate of recurrence of BOT and of invasive implants
- measure
- The rate of carcinoma recurrence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Women in menopause clinically defined as absence of menstrual cycle for 12 months * Primary diagnosis of BOT confirmed by pathological examination * Surgical treatment of BOT by BSO with (group 1) and without (group 2) hysterectomy * Informed consent acquisition Exclusion Criteria: * Occurrence of BOT at index intervention * Stage IV * Metastatic disease * Patients with previous hysterectomy * Cancer synchronous of the endometrium * Patients who have not had follow-up before 5 years (excluding those who have not reached the 5 year follow-up for the following events: death from any cause, death from BOT, recurrence of BOT)
References
Publications (0)
Data not yet available